Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)

Contributed by: PR Newswire

Tags

Swedish-Orphan-Biovit

More Like This

EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)

New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia

Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions

TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)

Tryngolza ® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

NICE issues final draft guidance recommending ▼ Tryngolza® (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales

Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

PR Newswire associated0

Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia